Corrigendum to: “Aptamer/doxorubicin-conjugated nanoparticles target membranous CEMIP2 in colorectal cancer” [Int. J. Biol Macromol. 245 (2023) Jun 21; 125510/Online ahead of print. PMID: 37353120; IJBIOMAC-D-23-03903R1](S0141813023024042)(10.1016/j.ijbiomac.2023.125510)
International Journal of Biological Macromolecules
Volume
248
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Biological Macromolecules Vol.248 (2023)
Suggested Citation
Kianpour M., Huang C.W., Vejvisithsakul P.P., Wang J.Y., Li C.F., Shiao M.S., Pan C.T., Shiue Y.L. Corrigendum to: “Aptamer/doxorubicin-conjugated nanoparticles target membranous CEMIP2 in colorectal cancer” [Int. J. Biol Macromol. 245 (2023) Jun 21; 125510/Online ahead of print. PMID: 37353120; IJBIOMAC-D-23-03903R1](S0141813023024042)(10.1016/j.ijbiomac.2023.125510). International Journal of Biological Macromolecules Vol.248 (2023). doi:10.1016/j.ijbiomac.2023.125782 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/88822
Title
Corrigendum to: “Aptamer/doxorubicin-conjugated nanoparticles target membranous CEMIP2 in colorectal cancer” [Int. J. Biol Macromol. 245 (2023) Jun 21; 125510/Online ahead of print. PMID: 37353120; IJBIOMAC-D-23-03903R1](S0141813023024042)(10.1016/j.ijbiomac.2023.125510)
The authors regret misassembled Fig. 3 while revising and providing a correct version of Fig. 3 in the attached file. The authors would like to apologize for any inconvenience caused. Please kindly help us with the corrigendum.[Formula presented]
